September 01, 2026 08:16 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
CJP calls off Sept 5 Delhi march after Supreme Court quashes FIRs against protesters | ‘Dismantle entire terror ecosystem’: Modi’s strong message at SCO Summit in Shehbaz’s presence | Modi’s big appeal after 7.8% GDP growth: ‘Don’t travel abroad, avoid destination weddings’ | Modi-Pezeshkian talks: Iran seeks India’s 'extensive contacts' to end West Asia war | Indus Waters Treaty row: India rejects Hague court order, says ‘no jurisdiction’ over its sovereign decisions | India beats the odds with 7.8% GDP growth; PM Modi has a message for critics | PM Modi meets Iranian President Masoud Pezeshkian during SCO summit in Kyrgyzstan | ‘Islam superior to all religions’: Karnataka minister’s remark sparks BJP-Congress war; resignation demand grows | PM Modi meets Iran's President Masoud Pezeshkian during SCO summit in Kyrgyzstan | VHP breaks silence on Durga Puja ‘guidelines’: No blanket non-veg ban, clarifies stand on theme pandals amid backlash
Corona Remedies
Corona Remedies listed at 38% premium. Photo: ChatGPT

Corona Remedies storms Dalal Street! Shares list at 38% premium on debut

| @indiablooms | Dec 15, 2025, at 11:19 am

Mumbai/IBNS: Pharmaceutical firm Corona Remedies made a strong debut on the stock market on Monday, listing at a 38% premium over its IPO price on the National Stock Exchange (NSE), media reports said.

The company’s shares were listed at ₹1,470 apiece on the NSE, marking a 38.42% premium over the issue price.

On the BSE, the stock debuted at ₹1,452 per share, a 36.72% premium.

The ₹655.37-crore IPO, which was entirely an offer for sale, had a price band of ₹1,008–1,062 per share and was open for subscription from December 8 to 10.

Headquartered in Ahmedabad, Gujarat, Corona Remedies is an Indian pharmaceutical company with a strong presence in branded generics, catering to both chronic and acute therapy segments.

The robust listing underscored strong investor confidence in the company’s growth outlook and financial performance, reflecting sustained demand for quality pharma IPOs in the Indian market.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.